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Vascular smooth muscle cells (VSMC) growth plays a key role in the pathophysiology of vascular diseases. However, the molecular
mechanisms controlling gene transcription in VSMC remain poorly understood. We previously identiﬁed, by diﬀerential display,
a new gene (6A3-5) overexpressed in proliferating rat VSMC. In this study, we have cloned the full-length cDNA by screening a rat
foetal brain cDNA library and investigated its functions. The 6A3-5 protein shows 4 putative conserved functional motifs: a DNA
bindingdomaincalledARID(AT-richinteractiondomain),tworecentlydescribedmotifs(OsaHomologyDomain),andanuclear
localization signal. The deduced protein sequence was observed to be 85% identical to the recently described human Osa2 gene.
Immunolabelling, using an anti-6A3-5/Osa2 monoclonal antibody, showed a nuclear localization of the 6A3-5/Osa2 protein. In
addition, PDGF upregulated 6A3-5/Osa2 expression at both the transcript and protein levels in a dose and time-dependent fash-
ion. The pattern of upregulation by PDGF was reminiscent of the early responsive gene c-fos. The PDGF-induced upregulation
of 6A3-5/Osa2 and proliferation of VSMC were signiﬁcantly inhibited in a dose and sequence-dependent fashion by an antisense,
but not by sense, scrambled or mismatched oligonucleotides directed against 6A3-5/Osa2. In VSMC of aortas derived from hyper-
tensive (LH) rats, 6A3-5/Osa2 is overexpressed as compared to that in normotensive (LL) rats. The 6A3-5/Osa2-gene expression
is downregulated by an ACE inhibitor and upregulated by exogenous AngiotensinII in LH rats. In summary, these results indicate
that 6A3-5/Osa2 is an early activated gene that belongs to a new family of proteins involved in the control of VSMC growth.
Copyright © 2006 Gwenaele Garin et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Vascular smooth muscle cell (VSMC) growth plays a critical
role in diﬀerent pathological conditions such as atheroscle-
rosis [1] and its clinical complications. Indeed, develop-
ment of these vascular diseases is associated with a loss
of vascular contractility counterbalanced by an increase of
VSMC migration, proliferation, matrix secretion, and, in
some cases, hypertrophy [2]. Diﬀerent agonists modulate
VSMC phenotype and activities in the vessel wall. For ex-
ample, platelet-derived-growth factor (PDGF), particularly
PDGF-BB, stimulates both proliferation and migration [3].
AngiotensinII (AngII), the active biological peptide of the
renin-angiotensin system, has potent vasoconstrictor actions
The ﬁrst two authors are considered joint ﬁrst authors of this work.
and is directly involved in the development of hypertension.
AngII induces a multitude of signalling pathways which, de-
pending on the VSMC phenotype, can lead to contraction,
hyperplasia, or hypertrophy [4, 5]. Many transcription fac-
t o r s( s u c ha sc - f o s[ 6], Ets-1 [7], NFκB[ 8]) and the sub-
sequent expression of a large number of genes (eg, alpha-
actin, Collagen IV, MCP-1, Endothelin-1, PDGF-A, TSP-1,
bFGF,andPDGFA-chain[9])arestimulatedbyAngII.How-
ever, the molecular mechanisms controlling gene transcrip-
tion during these processes remain at this stage poorly un-
derstood.
Anewgene(6A3-5/Osa2),whichisoverexpressedinpro-
liferating, rat aortic VSMC, was initially identiﬁed by diﬀer-
ential display [10]. This partially cloned gene of 1.2kb,not
referenced in Genbank, shares sequences homologies with
the ARID (AT-rich interaction domain) transcription mod-
ulator family. ARID-containing proteins are involved in the2 Journal of Biomedicine and Biotechnology
control of transcription during cell growth and embryonic
development [11, 12]. However, their precise functions are
not fully understood. In the current study, we have cloned
the full-length rat 6A3-5/Osa2 cDNA and characterized its
deduced protein sequence as a member of the ARID family.
Moreover, the knock-down of 6A3-5/Osa2 expression, which
is overexpressed in PDGF-dose and time-dependant man-
ner, resulted in a signiﬁcant reduction of VSMC prolifera-
tion. In vivo work showed that 6A3-5/Osa2 is overexpressed
in SMC of aortas derived from hypertensive (Lyon hyperten-
sive, LH) but not normotensive (Lyon low-blood pressure,
LL) rats. The 6A3-5/Osa2-gene expression is downregulated
by an ACE inhibitor and upregulated by exogenous AngII in
hypertensive rats.
MATERIALS AND METHODS
Isolationofafull-length6A3-5ratcDNA
A 6A3-5 full-length cDNA was cloned by screening a rat
foetal brain cDNA library (Origene Technologies, Inc) us-
ing primers generated from a previously derived partial se-
quence (Genbank accession number: AJ005202) [10], com-
bined with in silico analysis of genome databases. BlastA
(NCBI) and multiple alignments performed using ClustalW
(EBI) were used for assessing sequence homologies.
Cellculture
Primary human and rat VSMC were cultured as previously
described [13]. VSMC, at 80% of conﬂuence, were serum
starved for 48h and stimulated by PDGF-BB. Dose-eﬀect (0
t o2 0n g / m l )a n dt i m e - r e s p o n s e( 0 ,2 ,4 ,8 ,o r2 4h )e x p e r -
iments were performed on human VSMC. Following treat-
m e n t ,V S M Ca r eh a r v e s t e di nT r i z o lo ri nl y s i sb u ﬀer (1%
of 10mM aprotinin, 10mM leupeptine, 10mM EDTA, and
1mM phenylmethylsulfonyl ﬂuoride, 25mM Tris pH 7.6,
150mM NaCl, and 1% Triton X100).
Immunoﬂuorescence
After ﬁxation and permeabilization (100% methanol at
−20◦C during 5min), nonspeciﬁc sites were blocked
(PBS/3%BSA) for 1 hour at 25◦C. The primary antibody
(6H3 anti-Osa2 hybridoma supernatant (1 : 5) [14], mouse
anti-α-actin monoclonal antibody (1 : 100) or a rabbit anti-
NFKB polyclonal antibody (1 : 100), Dako) was incubated
for 2 hours at 25◦C. After 3 washing steps, VSMC were incu-
batedintheblockingsolutionwithanappropriatesecondary
antibody-FITC-conjugated (Dako) for 1 hour at 37◦C. After
4 washing steps, coverslips were mounted and analysed by
ﬂuorescence microscopy.
Northernblot
Total RNA was isolated according to the Trizol procedure.
Northerns were performed as previously described [15]. The
abundance of 6A3-5/Osa2 mRNA was normalized with re-
spect to 18S rRNA and the ratio expressed in arbitrary units
(au).
Westernblot
Nitrocellulose membrane bearing electrotransfered proteins
(30μg), separated on 7% SDS-polyacrylamide gels, were
blocked for 4 hours at 37◦Cw i t hT B S /0 .05% Tween20/3%
gelatine, and incubated overnight at 4◦C with an anti-Osa2
antibody (6H3, 1 : 5 [14]). A swine anti-mouse antibody,
conjugated to horseradish peroxidase (Bio-Rad), was then
used with a chemiluminescent technique (ECL kitTM, Amer-
sham). Expression level of 6A3-5/Osa2 protein was esti-
mated by Quantity One tool (Bio-Rad) and normalized with
Coomassie blue staining.
Geneknock-downbyantisenseoligonucleotides
The sequences and locations of the generated oligonu-
cleotides targeted against human Osa2 cDNA AF468300 are
summarized in Table 1. For transfection experiments, VSMC
at 60–70% of conﬂuence were serum-starved for 48h and
then incubated with 25–200nM ODN at concentration in
serum- and antibiotic-free MEM medium in the presence of
oligofectamine(Invitrogen).After4hours,VSMCwerestim-
ulatedbyPDGF(20ng/ml)fordiﬀerentperiodsoftime(0,2,
4, 6, and 24h) and then harvested in a cell lysis buﬀer or Tri-
zol. Alternatively, after transfection, VSMC were stimulated
by PDGF for 24 hours and used for Bromodeoxyuridine in-
corporation test (Roche) to estimate cell proliferation.
Animalstudies
Protocols for animals’ (Lyon hypertensive (LH) and Lyon
low-bloodpressure(LL)strains)housingandtreatmenthave
been previously detailed [16]. Three groups were used: the
ﬁrst group (controls, n = 8) was untreated and used as con-
trols. The second group (Ace I, n = 8) was treated with
an ACE inhibitor, perindopril (3mg/kg/d), for 4 weeks. The
third group (Ace I+ANGII, n = 8) was treated with an
ACE inhibitor, perindopril (3mg/kg/d) and perfused subcu-
taneously with AngII (200ng/kg/min) for 4 weeks.
Quantiﬁcationof6A3-5/Osa2mRNAby
quantitative-PCR
Frozen rat aortas were homogenized at 0◦C in 500μlT r i z o l
and total RNA isolated. Reverse transcription product (Su-
perscript II, Invitrogen) was used for quantitative real-time
PCR (Q-PCR) on an ABIPrism 7900. Q-PCR assay was car-
ried out using the Assay-on-Demand for 6A3-5, calponin,
SM22-alpha, and 18S mRNA levels were using the compara-
tive Ct method.
Immunohistochemistry
Immunohistochemistry was performed on frozen aorta sec-
tions (5μm) ﬁxed in acetone as previously described [15]
with an anti-Osa2 hybridoma supernatant (6H3) [14]o r
an anti-α-actin (Dako) monoclonal antibody. Primary an-
tibody binding was detected using a secondary antibodyGwenaele Garin et al 3
Table 1: Homologies of rat 6A3-5 sequences with ARID proteins. Homologues are divided into two subgroups. The ﬁrst subgroup, which
woulddeﬁnethesubfamilycalledOsa,hasmembersbearinganARIDmotifandtwoOHDdomains.Thesecondsubgroupindicatesdiﬀerent
ARID proteins.
Species Yeast Drosophila Mouse Human
S
u
b
g
r
o
u
p
1
Names Swi1 Osa, eyelid Osa1 Osa1, P270, B120, BAF250
Accesion no M84390 AF053091 AF268912 AF521670
Chromosome no — 3 4 1p35-p36
cDNA Length 3027bp 10601bp 7041bp 6418bp
Protein Length 825aa 2715aa 1902aa 1999aa
Functions –M e m b e ro f
yeast SWI/SNF
– Member of Brahma complex
– Antagonize wingless pathways
– Interaction with Brahma
chromatin remodelling
complex
– Member of human swi/snf
– Co-factor of transcriptional
activation by the steroid
hormone receptors
Name nd nd nd Osa2, held/Osa1, KIAA1235
Accesion no — — — AF521671 and AF468300
Chromosome no — — — 6q25.1–q25.3
cDNA Length — — — 5482pb
Protein Length — — — 1740aa
Functions —— —
– Member of human swi/snf
– Promotes transcriptional
activation by the steroid
hormone receptors
S
u
b
g
r
o
u
p
2
Name nd Dead Ringer (Dri) Bright DRIL-1
Accesion no — U62542 U60335 U88047
Chromosome no — — 10 19p13.3
cDNA Length — 3696bp 4842bp 2725pb
Protein Length — 901aa 601aa 593aa
Functions —
– Embryo patterning
– Target sequence:
AGATT/ATAA
–B - C e l la c t i v a t o r
– Target sequence:
AGATTAA
– Binds the pRb
controlled transcription
– Target sequence:
A/GATT/ATAA
Name nd nd Mrf2 Mrf2
Accesion no — — AF280065 M733837 (partial sequence)
Chromosome no — — 10 10
cDNA Length — — 3647bp —
Protein Length — — 1188aa —
Functions ——
– Accumulation of
lipids in postnatal life
– Target sequence:
AATA(C/T)
—
Name nd nd Jumonji Jumonji
Accesion no — — BC05244 U57592
Chromosome no — — — 6q24.p23
cDNA Length — — 4939bp —
Protein Length — — 1324aa 1266aa
Functions —— – N e u r a l e m b r y o g e n e s i s Highly expressed by neuron
cells during development4 Journal of Biomedicine and Biotechnology
Table 2: List of antisens oligonucleotides directed against 6A3-5.S e -
quence and position (on human homologous held/Osa2) of diﬀer-
ent ODN directed against 6A3-5. Only ODNAS3 showed signiﬁ-
cant eﬀects on 6A3-5 expression. Scrambled ODN3 (ODN Scr3)
and mismatched (ODN Mis3) as used to test sequence speciﬁcity
of ODNAS3.
Name Sequence 5 –3  Position/AF468300
ODNAs1 agcttgtcgaacttactggct 3870–3890
ODNAs2 cagcttgtcgaacttactggctt 3869–3889
ODNAs3 tgggatctgcccatg 57–71
ODN Scr3 agctcggttcacggt —
ODN Mis3 agggagctaccc ctg 57–71
ODNAs4 tcacatctgagaatgg 2245–2260
conjugated to horseradish peroxidase followed by 3-amino-
9-ethylcarbazole (Dako). The speciﬁc location of the α-actin
in the media of aorta was used to deﬁne the medial bound-
aries. The media thickness was then measured at a magni-
ﬁcation of X40 in slides counterstained with Haematoxylin
(Dako).
RESULTS
Cloningoffull-lengthrat6A3-5cDNA
The cloned gene has a 6569bp cDNA sequence (Gen-
Bank accession number: AJ440711) and a deduced amino
acid sequence corresponding to a 5276bp open-reading
frame (Figure 1(a)). The cDNA contained 1268bp in the 3 -
untranslated region; the 5 -untranslated sequence is not to-
tally cloned. The putative 1758 amino acid 6A3-5 protein has
anexpectedmolecularweightof180kDaandbearsfourcon-
served motifs (Figure 1(b)). The ﬁrst motif is a DNA bind-
ing domain, called AT-rich interaction domain or ARID, lo-
catedintheN-terminalhalf(aa568to672).Twoothermotifs
comprising evolutionary conserved domains known asOHD
(OsaHomologyDomain)-1(aa1114to1200)andOHD2(aa
1437 to 1758) are present within the C-terminal half of the
protein.Thesethreemotifsarethesignatureofanovelfamily
of transcription modulators called Osa family and indicate
that 6A3-5 is the rat Osa2 homologue. Finally, a fourth mo-
tif represented by a nuclear localization signal is also present
in the C-terminal of 6A3-5/Osa2 sequence suggesting a nu-
clear localization of this protein that was subsequently con-
ﬁrmed.
Multiplesequencealignmentandhomologies
torat6A3-5/Osa2
Protein similarity searches revealed two subgroups with sig-
niﬁcant homologies to rat 6A3-5/Osa2 protein. The 1st sub-
group comprises proteins bearing ARID, OHD1, and OHD2
functional domains. This group shows a remarkably high
degree of conservation of amino acid sequences, and in-
cludes the recently cloned human Osa2 [14]. This protein
appears to be the human orthologue of rat 6A3-5/Osa2,
mouse, and human Osa1 [17], Drosophila Osa/eyelid [18]
and yeast SWI1 protein [19]( Figure 2). The 2nd subgroup
shows homologies that are limited to the ARID domain
and include Drosophila dead-ringer protein [20], its homo-
logues in mouse (bright) [21] and human (DRIL-1), mouse
Mrf2 [22], and the murine and human jumonji proteins
(Table 2).
Cellularlocalization
VSMC characterized with anti-α-actin antibody showed its
nucleus to be equally labelled with an anti 6A3-5/Osa2 [14]
or an anti-NFKB antibody. Negative controls showed no la-
belling (Figure 3).
6A3-5expressionindifferentphenotypeofvascularSMC
Transcription levels of 6A3-5/Osa2 and α-actin markers were
measuredafterdediﬀerentiationofexvivoSMCsfromacon-
tractile (passage 0, P0) to an in vitro synthetic phenotype
(passage 9, P9). Northern-blots showed that 6A3-5 is up-
regulated by 3-fold (n = 3) in the synthetic phenotype in
comparison to the contractile quiescent phenotype. In con-
trast, α-actin expression is present in the contractile SMCs
phenotype and lost on diﬀerentiation to a synthetic phe-
notype (Figure 4(a) and data not shown) [23]. The 6A3-
5/Osa2 gene was signiﬁcantly upregulated in a smooth mus-
cle cell line (V8) that was observed to be highly proliferat-
ing [24] compared with secretory/ synthetic cells (results not
shown).
TimecourseanddoseeffectofPDGFon
6A3-5/Osa2inVSMC
Humanandrat(datanotshown)VSMCwereserumstarved,
inducing a down-regulation of 6A3-5/Osa2 mRNA expres-
sion levels, and then treated with 20ng/ml of PDGF-BB for
0, 2, 4, 8, and 24 hours. Northern blot analysis showed that
the levels of 6A3-5/Osa2 mRNA reached a peak at 2 hours
and remained above the control level for at least 24 hours af-
terPDGFtreatment(Figure 5(a)).Inaddition,aPDGFdose-
dependant eﬀect was also observed with a maximal increase
achieved at 20ng/ml (Figure 5(b)). Similar results were ob-
served at 4 hours, by Western blot, for 6A3-5/Osa2-protein
expression (Figures 5(c), 5(d)).
AntisenseODNinhibitionof6A3-5/Osa2expression
andVSMCproliferation
A series of 20-base phosphorothioate antisense ODN
(Table 1,O D N AS1-4) was screened for its ability to selectively
inhibit 6A3-5/Osa2 protein expression in human VSMC.
After transfection, VSMC were stimulated by PDGF-BB
for 4 hours. The ODNAS3, which hybridizes to the 6A3-
5/Osa2 ATG translation initiation site, showed a signiﬁ-
cant inhibition of 6A3-5/Osa2 mRNA and protein expres-
sion in comparison to its sense, scrambled, and mismatched
controls (Figures 6(a), 6(b), 6(c)). Moreover, treatment of
human VSMC with increasing concentrations of ODNAS3Gwenaele Garin et al 5
        1 agccccggca cccctggacc gaccatgggc agatcccagg gcagtccgat ggacccaatg 
       61 gtgatgaaga gacctcagtt gtatgggatg ggcactcacc cccattcgca gccgcagcag 
      121 agcagcccat acccaggagg tgcctacggc cccccaggcg cacagcggta tccccttggc 
      181 atgcagggcc gggctccagg ggccctggga ggcttgcagt acccacagca gcagatgcca 
      241 cctcagtatg gacagcaagg tgtgagtggt tactgccagc agggccaaca gccatattac 
      301 agccagcagc cgcagccccc gcacctccca ccccaggcgc agtatctgcc gtcccagtcc 
      361 cagcagaggt accagccgca gcaggacatg tctcaggaag gctatggaac tagatctcaa 
      421 cctcctctgg cccccggaaa acctaaccat gaagacttga acttaataca gcaagaaaga 
      481 ccatcaagtt taccagatct gtctggctcc attgatgacc tccccacggg aacggaagca 
      541 actttgagct cagcagtcag tgcatccggg tccacgagca gccaagggga tcagagcaac 
      601 ccggcgcagt cgcctttctc cccacatgca tcccctcatc tctccagcat cccggggggc 
      661 ccatctccct ctcctgttgg ctctcctgta ggaagcaacc agtctcgatc tggcccaatc 
      721 tctcctgcaa gtatcccagg ttttatggca ggcacacaaa gaaaccctca gatggctcag 
      781 tatggacctc aacagacagg accatccatg tcgcctcatc cttctcctgg gggccagatg 
      841 catgctggaa tcagtcgctt tcagcagagt aactcaagtg ggacttacgg tccacagatg 
      901 agccagtatg gaccacaagg taactactcc agacccccag cgtatagtgg ggtgcccagt 
      961 gcaagctaca gcggcccagg gcccggtatg ggtatcagtg ccaacaacca gatgcatgga 
     1021 caagggccaa gccagccatg tggtgctgtg cccctgggac gaatgccatc agctgggatg 
     1081 cagaacagac catttcctgg aaatatgcgc agcatgcccc ccagttctcc tggcatgtct 
     1141 cagcagggag ggccaggaat gggccgggca ccaggcccac caatgcccac tgtgaaccgc 
     1201 aaggcccagg aagctgccgc ggctgtgatg caggctgctg caaactcagc ccaaagcagg 
     1261 caaggcagct ttcctggcat gcaccagagt ggactcgtgg cctccagctc tccctacagc 
     1321 cagcccatga acaacaactc caacctaatg ggcacacagg cccagcccta cagcatcaca 
     1381 cccaccatgg tgaacagctc tacagcatct atgggtctta cagatatgat gtctcccagt 
     1441 gtgtccaaac tgtccgtgcc tctcaaagca gatggcaaag aagaaggtgt gccccagccc 
     1501 gagagcaagt caaaggatag ctacagctct cagggtattt ctcagcctcc aactccaggc 
     1561 aacctgccag tcccttcccc aatgtccccc agctctgcca gcatctcctc ctttcacgga 
     1621 gatgagagtg acagcattag cagcccaggc tggcccaaga ctccatcaag ccccaagtcc 
     1681 agctcctctt ccaccactgg ggagaagatc acaaaagtgt acgagctggg gactgcgccg 
     1741 gagaggaagc tgtgggtcga ccgctacctc acattcatgg aggagagggg gtcccccgtg 
     1801 tccagtctgc cggcagtggg caagaagccc ctggacctgt tccgactcta tgtgtgcgtc 
     1861 aaagagatcg gaggcttggc gcaggttcat acaaacaaga agtggcgcga gctggcaacc 
     1921 aacccgaacg ttggcacttc gagcagcgca gccagctccc cgaagaagca atatattcag 
     1981 tacctgttcg ccttcgagtg caaaatcgag cgtggggagg agcccccgcc ggaagtcttc 
     2041 agcacggggg atgcgaagaa gcagcccaag ctccagccgc catctcctgc caactcggga 
     2101 tccttacaag gtccacagac gccacagtca actggcagca gttccatggc agaggttccc 
     2161 ggcgacccga agccaccaac cccagcctcc acccctcacg gacaggggac ccccatgcaa 
     2221 agcggaagaa gcagtacagt cagtgtgcac gacccgttct cagacgtgag tgattcagcg 
     2281 tacccaaaac ggaactccac gactccaaac gccccatacc agcagggcat gggcatgcca 
     2341 gacatgttgg gcaggatgcc ctatgcgccc aacaaggacc ctttcagtgg aacgagaaaa 
     2401 gtgcctggaa gcagcgagcc ctttatgaca caaggacaga tgcccaacag cagtatgcag 
     2461 gacatgtaca accagagtcc ctcaggtgcc atgtccaatc tgggcatggg acagcggcag 
     2521 caatttccct atggaaccag ttacgaccga aggcacgagg cttacgggca gcagtaccca 
     2581 ggccaaggcc ctcccacagg acagccaccg tatggaggac accagcctgg cctgtaccca 
     2641 cagcagccga attacaaacg ccatatggat ggcatgtacg ggcctccagc caagcgccac 
     2701 gagggagaca tgtacaacat gcagtatggc agccaacagc aggagatgta caaccagtac 
     2761 ggaggctcct actctggccc ggacagaagg cccatccagg gacagtatcc ctacccctac 
     2821 aacagagaaa ggatgcaggg cccaggccag atgcaaacag atggaatccc acctcacatg 
     2881 atgggtggcc ccatgcagtc atcttccaat gaggggcctc agcagaatat gtgggctaca 
     2941 cgcaatgata tgccttatcc ctaccagaac aggcaaggcc caggtggccc tgcacaggca 
     3001 cccccttacc caggcatgaa ccgcacagat catatgatgg tacctgatca gaggatcaat 
     3061 cacgagagcc agtggccttc tcatgtcagc cagcgccagc cttatatgtc atcatcggcc 
     3121 tccatgcaac ccatcacgcg cccacctcag tcatcctacc agacgccgcc gtcactgcca 
     3181 aaccacatct ccagggcacc cagccctgcc tccttcccgc gctccctgga gagccgcatg 
     3241 tctccaagca agtccccctt cctgcctgcc atgaagatgc agaaggtcat gcccacggtc 
     3301 cccacatccc aggtcaccgg accaccccca cagccaccgc caatcagaag ggagattacc 
     3361 tttcctcctg gctcagtaga agcatcgcag ccagtcccga aacaaaggcg gaagattacc 
     3421 tcaaaagata ttgttactcc cgaggcgtgg cgtgtgatga tgtcccttaa atccggtctg 
     3481 ttggctgaga gcacgtgggc tttggacacc atcaacattc tcctctatga tgacagcact 
     3541 gtcgccacct tcaatctttc ccagctgtcg gggttcctgg aactactagt ggagtacttc 
     3601 cgaaagtgcc taattgacat tttcggtatt cttatggaat atcaagtggg cgaccccagc 
     3661 caaagggcgc tcgatcaccg cacagggaag aaagacgaca gccagtcctc ggaggacgac 
     3721 tctgggaaag aagaagaaga tgccgagtgt ctggaggagg aggaggagga ggaggaagag 
     3781 gaggaggagg aagaggagca agtcagtaaa aagacagagt cagagggcaa gagcagctct 
     3841 gccctagctg ctccagacac cactgcggac cccaaggaga cgccgaggca ggccagtaag 
     3901 ttcgacaagc tgcccataaa gattgtcaag aagaacaacc tgtttgtggt ggaccggtcc 
     3961 gacaggctgg gtcgggttca agagttcaac agcgggctcc tccactggca gctgggtggt 
     4021 ggcgacacca ccgagcacat cctcactcac ttcgagagca agatggagat ccctcctcgc 
     4081 aggcgtccac ctgcgcctct cagctccacg ggtaagaaga aagagctggc aggcaagggc 
     4141 gattctgaag agcagccaga gaaaagcatc atagccacca tcgatgatgt cctgtctgcc 
     4201 cgaccagggg ccctgccgga agacagcaac cccggacccc aaaccgagag cggcaagttt 
     4261 ccctttggaa tccagcaggc caaaagccac cggaacatca ggctcctgga ggacgagccc 
(a)
Figure 1: Full-length ORF sequence of rat 6A3-5, 6569pb. (a) The full-length rat 6A3-5 cDNA has a ﬁrst methionine that corresponds to an
ATG codon (position 25 underlined) and a stop codon (TGA, position 5301) followed by polyadenylation signal (position 6299). (b) ORF
translation sequence with 1758aa. Conserved motifs are indicated: ARID motif (568–672) is underlined, OHD motifs (OHD1: 1114-1200;
OHD2: 1437–1758) are boxed, and NLS (nuclear localization signal) (1352–1369) in bold.6 Journal of Biomedicine and Biotechnology
    4321 aggagccgag acgagactcc cctgtgcacc attgcgcact ggcaggactc cctggccaaa 
    4381 cgctgcatct gtgtgtccaa catcgtgcgg agcttgtctt tcgtgcctgg caacgacgca 
    4441 gagatgtcca aacatccggg cttggtgccg atcctaggaa agtcgattct gctgcatcat 
    4501 gagcatccgg agagaaaacg ggcgccacag acctatgaga aggaggagga tgaggacaag 
    4561 ggggtggcct gcagcaaaga tgagtggtgg tgggactgcc tcgaggtctt gcgggacaac 
    4621 acactggtca cattggctaa catttccggg cagctagact tgtctgctta cacagagagc 
    4681 atctgcttgc cgatcctgga cggcttgctg cactggatgg tgtgcccgtc tgcagaggca 
    4741 caggacccct ttcccactgt ggggcccaac tcagttctat cgccacaaag acttgtgctg 
    4801 gagacactgt gtaaactcag tatccaggac aacaatgtgg acctgatctt ggccacacct 
    4861 ccatttagtc gtcaggagaa attttatgct acattagtta ggtacgttgg ggatcgcaaa 
    4921 aacccagtct gccgagaaat gtccatggcg cttttatcga accttgccca gggggataca 
    4981 ctggcagcga gggcaatagc tgtgcagaaa ggaagcattg ggaacttgat aggcttcctg 
    5041 gaggacgggg tcacgatggc gcagtatcag cagagccagc ataccctcat gcacatgcag 
    5101 cccccgcctc tggaaccccc cagtgtggac atgatgtgca gggcggccaa agctttgctg 
    5161 gctatggcca gagtggatca gaaccgctcg gagttccttt tgcacgaggg tcggttgctg 
    5221 gatatctcga tatccgctgt cctgaactct ctggttgcgt ctgtcatctg tgatgtactg 
    5281 tttcagattg ggcagttatg acacccgtga gggcacacat gtgtgaggga acattagagg 
    5341 gtcacatatg actggctgtt ttctgttctc gtttatccaa tgtaggaaga aggaaaagaa 
    5401 aaatctttgc ttctctgccc cattcactat ttaccaattg ggaattaaag aaatcattaa 
    5461 tttgaacagt tataaattaa tatttgctgt ctgtgtgtat aagtacatcc gttgggggat 
    5521 ttctgtttct ttctcttttt tttaaccaaa gttgccgtct agtgcattca caggtcacat 
    5581 gtttttttgt ttttttcata atttttttca tgttgtatta cagttttagg gaagtgaatt 
    5641 cactttataa agtaaaaagg tttggcaaaa aatgctgata ggaaaatttc accacactga 
    5701 gtcaaaaagg tgaaaggaaa aattgatcct taaattgatt tcctatgaat tttattcttc 
    5761 gcagaatgaa aaaagcgaaa gtgcatccca ttgcccaaag ctctgtgcaa tagaaacttc 
    5821 tagagatgta ggtgtagggg ctcgaggtat ggcagtcagc agtctggccc agtgatgctg 
    5881 ttctctccac aggaaagcgg ttgcattagg cctcgagcaa aaaaccgcac tctcagttag 
    5941 gggtgaaaat ccactcctaa ccgccaacag caggattgct tcctcaccac gaccgccatg 
    6001 tctgctgcga ctcagcctcc acctcacaga tcttcgtgat tcctttcatc attttttaaa 
    6061 tatttttttt ttactgccta tgggctgtga tgtatataga agttgtacat taaacatacc 
    6121 ctcatatttt tttcttttct tttttttttt ttagtacaaa gtttttagtt tctttttcat 
    6181 gatgtggtaa ctacgaagtg atggtagatt taaataattt tttattttta ttttatatat 
    6241 tttttcatta ggaccatatc tccaaaaaac aagaaaaaga aacaaaaaat tacaaaaaat
    6301 taaacaaaca aaaaaagggg gtaatgtaca agtttctgta tgtataaagt catgctctgt 
    6361 tgggagggca gctggtccca atttgcttca tgaatcaagg tgtggaaatg gttgcatacg 
    6421 gattgattta gaaaatgaat accagtacat acaaaaaaaa agaaaaaaga aaaaccaact 
    6481 aaatgaagaa acacaacttc aaagattttt ctgtgacaag aatccgcatt tgtatttcaa 
    6541 gataatgtag tttaagaaaa aaaaaaaaa
(a)
        1 MGRSQGSPMD PMVMKRPQLY GMGTHPHSQP QQSSPYPGGA YGPPGAQRYP LGMQGRAPGA
       61 LGGLQYPQQQ MPPQYGQQGV SGYCQQGQQP YYSQQPQPPH LPPQAQYLPS QSQQRYQPQQ
      121 DMSQEGYGTR SQPPLAPGKP NHEDLNLIQQ ERPSSLPDLS GSIDDLPTGT EATLSSAVSA
      181 SGSTSSQGDQ SNPAQSPFSP HASPHLSSIP GGPSPSPVGS PVGSNQSRSG PISPASIPGF
      241 MAGTQRNPQM AQYGPQQTGP SMSPHPSPGG QMHAGISRFQ QSNSSGTYGP QMSQYGPQGN
      301 YSRPPAYSGV PSASYSGPGP GMGISANNQM HGQGPSQPCG AVPLGRMPSA GMQNRPFPGN
      361 MRSMPPSSPG MSQQGGPGMG RAPGPPMPTV NRKAQEAAAA VMQAAANSAQ SRQGSFPGMH
      421 QSGLVASSSP YSQPMNNNSN LMGTQAQPYS ITPTMVNSST ASMGLTDMMS PSVSKLSVPL
      481 KADGKEEGVP QPESKSKDSY SSQGISQPPT PGNLPVPSPM SPSSASISSF HGDESDSISS
      541 PGWPKTPSSP KSSSSSTTGE KITKVYELGT APERKLWVDR YLTFMEERGS PVSSLPAVGK
      601 KPLDLFRLYV CVKEIGGLAQ VHTNKKWREL ATNPNVGTSS SAASSPKKQY IQYLFAFECK
      661 IERGEEPPPE VFSTGDAKKQ PKLQPPSPAN SGSLQGPQTP QSTGSSSMAE VPGDPKPPTP
      721 ASTPHGQGTP MQSGRSSTVS VHDPFSDVSD SAYPKRNSTT PNAPYQQGMG MPDMLGRMPY
      781 APNKDPFSGT RKVPGSSEPF MTQGQMPNSS MQDMYNQSPS GAMSNLGMGQ RQQFPYGTSY
      841 DRRHEAYGQQ YPGQGPPTGQ PPYGGHQPGL YPQQPNYKRH MDGMYGPPAK RHEGDMYNMQ
      901 YGSQQQEMYN QYGGSYSGPD RRPIQGQYPY PYNRERMQGP GQMQTDGIPP HMMGGPMQSS
      961 SNEGPQQNMW ATRNDMPYPY QNRQGPGGPA QAPPYPGMNR TDHMMVPDQR INHESQWPSH
     1021 VSQRQPYMSS SASMQPITRP PQSSYQTPPS LPNHISRAPS PASFPRSLES RMSPSKSPFL
     1081 PAMKMQKVMP TVPTSQVTGP PPQPPPIRRE ITFPPGSVEA SQPVPKQRRK ITSKDIVTPE
     1141 AWRVMMSLKS GLLAESTWAL DTINILLYDD STVATFNLSQ LSGFLELLVE YFRKCLIDIF
     1201 GILMEYQVGD PSQRALDHRT GKKDDSQSSE DDSGKEEEDA ECLEEEEEEE EEEEEEEEQV
     1261 SKKTESEGKS SSALAAPDTT ADPKETPRQA SKFDKLPIKI VKKNNLFVVD RSDRLGRVQE
     1321 FNSGLLHWQL GGGDTTEHIL THFESKMEIP PRRRPPAPLS STGKKKELAG KGDSEEQPEK
     1381 SIIATIDDVL SARPGALPED SNPGPQTESG KFPFGIQQAK SHRNIRLLED EPRSRDETPL
     1441 CTIAHWQDSL AKRCICVSNI VRSLSFVPGN DAEMSKHPGL VPILGKSILL HHEHPERKRA
     1501 PQTYEKEEDE DKGVACSKDE WWWDCLEVLR DNTLVTLANI SGQLDLSAYT ESICLPILDG
     1561 LLHWMVCPSA EAQDPFPTVG PNSVLSPQRL VLETLCKLSI QDNNVDLILA TPPFSRQEKF
     1621 YATLVRYVGD RKNPVCREMS MALLSNLAQG DTLAARAIAV QKGSIGNLIG FLEDGVTMAQ
     1681 YQQSQHTLMH MQPPPLEPPS VDMMCRAAKA LLAMARVDQN RSEFLLHEGR LLDISISAVL
     1741 NSLVASVICD VLFQIGQL
ARID
OHD1
OHD2
(b)
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HELD/Osa1    -----------KSSSSTTTGEKITKVYELGNEPERKLWVDRYLTFMEERGSPVSSLPAVG
HOsa2        -----------KSSSSTTTGEKITKVYELGNEPERKLWVDRYLTFMEERGSPVSSLPAVG
R6A3-5       SPGWPKTPSSPKSSSSSTTGEKITKVYELGTAPERKLWVDRYLTFMEERGSPVSSLPAVG
HOsa1        -----------KSSSSTTTNEKITKLYELGGEPERKMWVDRYLAFTEEKAMGMTNLPAVG
MOsa1        -----------KSSSSTTTNEKITQLYELGGEPERKMWVDRYLAFTEEKAMGMTNLPAVG
D,EYELID     -HVPVPQEPFRSTITTTKKSDSLCKLYEMDDNPDRRGWLDKLRAFMEERRTPITACPTIS
M,Bright     ---------------DWTFEEQFKQLYELDADPKRKEFLDDLFSFMQKRGTPVNRIPIMA
D,dead ringer-------------WSFEEQFKQVRQLYEINDDPKRKEFLDDLFSFMQKRGTPINRLPIMA
Y,SWI1       -------------ILQSLNPALQEKISTELNNKQYELFMKSLIENCKKRNMPLQSIPEIG
HELD/Osa1    KKPLDLFRLYVCVKEIGGLAQVNKNKKWRELATNLNVGTSS-SAASSLKKQYIQYLFAFE
HOsa2        KKPLDLFRLYVCVKEIGGLAQVNKNKKWRELATNLNVGTSS-SAASSLKKQYIQYLFAFE 
R6A3-5       KKPLDLFRLYVCVKEIGGLAQVHTNKKWRELATNPNVGTSS-SAASSPKKQYIQYLFAFE 
HOsa1        RKPLDLYRLYVSVKEIGGLTQVNKNKKWRELATNLNVGTSS-SAASSLKKQYIQCLYAFE 
MOsa1        RKPLDLYRLYVSVKEIGGLTQVNKNKKWRELATNLNVGTSS-SAASSLKKQYIQCLYAFE 
D,EYELID     KQPLDLYRLYIYVKERGGFVEVTKSKTWKDIAGLLGIGASS-SAAYTLRKHYTKNLLTFE 
M,Bright     KQVLDLFMLYVLVTEKGGLVEVINKKLWREITKGLNLPTSITSAAFTLRTQYMKYLYPYE 
D,dead ringerKSVLDLYELYNLVIARGGLVDVINKKLWQEIIKGLHLPSSITSAAFTLRTQYMKYLYPYE 
Y,SWI1       NRKINLFYLYMLVQKFGGADQVTRTQQWSMVAQRLQISDYQ---QLES--IYFRILLPYE 
HELD/Osa1    CKIERGEEPPPEVFSTGDTKK--QPKLQPPSPANSGSLQGPQTPQSTGSNSMAEVP----
HOsa2        CKIERGEEPPPEVFSTGDTKK--QPKLQPPSPANSGSLQGPQTPQSTGSNSMAEVP---- 
R6A3-5       CKIERGEEPPPEVFSTGDAKK--QPKLQPPSPANSGSLQGPQTPQSTGSSSMAEVP---- 
HOsa1        CKIERGEDPPPDIFAAADSKKS-QPKIQPPSPAGSGSMQGPQTPQST-SSSMAEG----- 
MOsa1        CKIERGEDPPPDIFAAADSKKS-QPKIQPPSPAGSGSMQGPQTHQST-SSSMAEG----- 
D,EYELID     CHFDRGDIDPLPIIQQVEAGSKKKTAKAASVPSPGGGHLDAGTTNSTGSSNSQDSFPAPP 
M,Bright     CER-RGLSSPNELQAAIDSNR--------------------------------------- 
D,dead ringerCEK-KNLSTPAELQAAIDGNR--------------------------------------- 
Y,SWI1       RHMISQEGIKETQAKRIFLQQFLQELLKKVQ------------------Q---------- 
ARID motif
1140
1200
1260
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
(a)
HELD/Osa1    PPGSVEASQPVLKQRRKITSKDIVTPEAWRVMMSLKSGLLAESTWALDTINILLYDDSTV
HOsa2        PPGSVEASQPVLKQRRKITSKDIVTPEAWRVMMSLKSGLLAESTWALDTINILLYDDSTV
R6A3-5       PPGSVEASQPVPKQRRKITSKDIVTPEAWRVMMSLKSGLLAESTWALDTINILLYDDSTV
HOsa1        PPGSVEATQPVLKQRRRLTMKDIGTPEAWRVMMSLKSGLLAESTWALDTINILLYDDNSI
MOsa1        PPGSVEATQPVLKQRRRLTMKDIGTPEAWRVMMSLKSGLLAESTWALDTINILLYDDNSI
D,EYELID     PHDSVESTTPVLYRRKRLTKADVCPVDPWRIFMAMRSGLLTECTWALDVLNVLLFDDSTV
M,Bright     --VSLAGHP-------------VVAAQAAAVQAAAAQAAVAAQAAALEQL----------
D,dead ringerQQQRQRSQSPDLSKHEALS----AQVALWHMYHNNNSPPGSAHTSPQQRE----------
Y,SWI1       NYISKIGEKIDSNKPIFLFAPELGAINLHALSMSLQSKNLGEINTALNTLLVTSADSN—
HELD/Osa1 ATFNLSQLSGFLELLVEYFRKCLIDIFGILMEYEVGDPSQKALDHNAARKDDSQSLANDS
HOsa2        ATFNLSQLSGFLELLVEYFRKCLIDIFGILMEYEVGDPSQKALDHNAARKDDSQSLADDS
R6A3-5       ATFNLSQLSGFLELLVEYFRKCLIDIFGILMEYQVGDPSQRALDHRTGKKDDSQSSEDDS
HOsa1        MTFNLSQLPGLLELLVEYFRRCLIEIFGILKEYEVGDPGQRTLLD-PGRFSKVSSPAPME
MOsa1        MTFNLSQLPGLLELLVEYFRRCLIEIFGILKEYEVGDPGQRTLLD-PGRFTKVSSPAHTE
D,EYELID     QFFGISNLPGLLTLLLEHFQKNLAEMFDERENEEQSALLAEDADDDADSGTVMCEKLRTS
M,Bright     ------------------------------------------------------------
D,dead ringer-ALNLSDS-------------------------------PPNLTN---------------
Y,SWI1       LKISLVKYPELLDSLAILG----MNLLSNLSQNVVPYHRNTSDYYYEDAGSNQYYVTQHD
OHD1
1980
2040
(b)
Figure 2: Alignments of conserved domains of ARID proteins by CLUSTALW program. (a) ARID motif alignment among diﬀerent species is
shown. (b) OHD-1 (Osa hoomology domain-1) motif alignment. (c) OHD-2 (Osa hoomology domain-1) motif alignment. Conserved aa
residues are shown by underlining. Identical residues are indicated in grey. H: human, r: rat, M: Mouse, d: Drosophila, Y: yeast (hELD/OSA1
or hOsa2: human homolog of 6A3-5/Osa2).
(25, 100, 200nM) resulted in a dose-dependent reduction
in 6A3-5/Osa2 protein level (Figure 6(d))b u th a dn oe f -
fect on P53 expression. Indeed, 6A3-5/Osa2 expression is
reduced by 60–70% in presence of 200nM of antisense
ODNAS3.
To investigate whether reduction of 6A3-5/Osa2 expres-
sionaﬀectedPDGF-inducedproliferation,serumstarvedhu-
m a nV S M Cw e r ee x p o s e dt oO D N AS3 and then stimulated
by PDGF-BB for 24 hours. ODNAS3 reduced by 50–60%
PDGF-induced proliferation in human VSMC (Figure 7(a))
while sense, scrambled, or mismatched oligonucleotides de-
rived from ODNAS3 had no eﬀect. Moreover, increasing
the concentration of ODNAS3 signiﬁcantly reduced PDGF-
induced proliferation of VSMC in a dose-dependent manner
(Figure 7(b)).
Expressionof6A3-5/Osa2andvascularPhenotype
inLHversusLLrats
Quantitative PCR performed on aorta excised from hy-
pertensive (LH) rats exhibited signiﬁcantly increased
6A3-5/Osa2 gene expression levels compared to those
present in normotensive (LL) rats (Figure 8(a)). A signiﬁ-
cant decrease in VSMC contractile markers, calponin and8 Journal of Biomedicine and Biotechnology
HELD/Osa1    KFPFGIQQAKS-------------------HRNIKLLEDEPRSRDETPLCTIAHWQDSLA
HOsa2        KFPFGIQQAKS-------------------HRNIKLLEDEPRSRDETPLCTIAHWQDSLA 
R6A3-5       KFPFGIQQAKS-------------------HRNIRLLEDEPRSRDETPLCTIAHWQDSLA 
HOsa1        KFPFGISPAQS-------------------HRNIKILEDEPHSKDETPLCTLLDWQDSLA 
MOsa1        KFPFGISPAQS-------------------HRNIKILEDDPHSKDETPLCTLLDWQDPLA 
D,EYELID     RLTNGVAPCSSTPAIFDPRTTAKDEARVLQRRRDSSFEDECYTRDEASLHLVSESQDSLA 
M,Bright     ---------------------------------------------EKKMALVADEQQRLM 
D,dead ringerDYAHG---------------------------------EHNTTGNSSSMHDDSEPQQMNG 
Y,SWI1       ILNFKKDLVIVLS------------------NISHLLEIASSIDCLLILILVISFGQPKL 
HELD/Osa1    KRCICVSNIVRSLSFVPGNDAEMSKHPGL-VLILGKLILLHHEHPERKRAPQTYEKEEDE
HOsa2        KRCICVSNIVRSLSFVPGNDAEMSKHPGL-VLILGKLILLHHEHPERKRAPQTYEKEEDE 
R6A3-5       KRCICVSNIVRSLSFVPGNDAEMSKHPGL-VPILGKSILLHHEHPERKRAPQTYEKEEDE 
HOsa1        KRCVCVSNTIRSLSFVPGNDFEMSKHPGL-LLILGKLILLHHKHPERKQAPLTYEKEEEQ 
MOsa1        KRCVCVSNTIRSLSFVPGNDFEMSKHPGL-LLILGKLILLHHKHPERKQAPLTYEKEEEQ 
D,EYELID     RRCIALSNIFRNLTFVPGNETVLAKSTRF-LAVLGRLLLLNHEHLRRTPKTRNYDREEDT 
M,Bright     QRAVQQS-FLAMTAQLPMN--------------IR----INSQASESRQDSAVSLTSANG 
D,dead ringerHHHHQTHHLDKSDDSAIENSPTTSTTTG------GSVGHRHSSPVSTKKKGGAKPQSGGK 
Y,SWI1       NPMASSSSFGSESLTFNEFQLQWGKYQTFGVDILAKLFSLEKPNLNYFKSILLNKNTGNN 
HELD/Osa1    DKGVACS----KDEWWWDCLEVLRDNTLVTLANISGQLDLSAYTESICLPILDGLLHWMV
HOsa2        DKGVACS----KDEWWWDCLEVLRDNTLVTLANISGQLDLSAYTESICLPILDGLLHWMV
R6A3-5       DKGVACS----KDEWWWDCLEVLRDNTLVTLANISGQLDLSAYTESICLPILDGLLHWMV
HOsa1        DQGVSCN----KVEWWWDCLEMLRENTLVTLANISGQLDLSPYPESICLPVLDGLLHWAV
MOsa1        DQGVSCD----KVEWWWDCLEMLRENTLVTLANISGQLDLSPYPESICLPVLDGLLHWAV
D,EYELID     DFSDSCSSLQGEREWWWDYLITIRENMLVAMANIAGHLELSRYDELIARPLIDGLLHWAV 
M,Bright     SNSISMS-----------VEMNGIVYTGVLFAQPP----------------------PPT 
D,dead ringerDLPTEDK----------DASSSGKLNPLETLSLLSG-------------------MQFQV 
Y,SWI1       LYDRNSN------NNHKDKKLLRRLLNLYNDNNKNNNNRHNLLNDVVSFLFSAIPLQQVL 
HELD/Osa1    CPSAEAQDPFPTVGPNSVLSPQRLVLETLCKLSIQDNNVDLILATPPFSRQEKFYATLVR
HOsa2        CPSAEAQDPFPTVGPNSVLSPQRLVLETLCKLSIQDNNVDLILATPPFSRQEKFYATLVR 
R6A3-5       CPSAEAQDPFPTVGPNSVLSPQRLVLETLCKLSIQDNNVDLILATPPFSRQEKFYATLVR 
HOsa1        CPSAEAQDPFSTLGPNAVLSPQRLVLETLSKLSIQDNDVDLILATPPFSHLEKLYSTMVR 
MOsa1        CPSAEAQDPFSTLGPNAVLSPQRLVLETLSKLSIQDNNVDLILATPPFSRLEKLYSTMVR 
D,EYELID     CPSAHGQDPFPSCGPNSVLSPQRLALEALCKLCVTDANVDLVIATPPFSRLEKLCAVLTR 
M,Bright     APSAPGKGGVSSIGTN--------------------------TTTG--SR---------- 
D,dead ringerARNGTGDNGEPQLIVNLELNGVKYS----------G----VLVANVPLSQ---------- 
Y,SWI1       SQSADPSLLIDQFSPVISQSLTSILVIVQKILPLSNEVFEISENNSDSNSNNN------- 
HELD/Osa1    YVGDRKNPVCREMSMALLSNLAQGDALAARAIAVQKGSIGNLISFLEDGVTMAQYQQSQH
HOsa2        YVGDRKNPVCREMSMALLSNLAQGDALAARAIAVQKGSIGNLISFLEDGVTMAQYQQSQH 
R6A3-5       YVGDRKNPVCREMSMALLSNLAQGDTLAARAIAVQKGSIGNLIGFLEDGVTMAQYQQSQH 
HOsa1        FLSDRENPVCREMAVVLLANLAQGDSLAARAIAVQKGSIGNLLGFLEDSLAATQFQQSQA 
MOsa1        FLSDRKNPVCREMAVVLLANLAQGDSLAARAIAVQKGSIGNLLGFLEDSLAATQFQQSQA 
D,EYELID     HLCRNEDQVLREFSVNLLHYLAAADSAMARTVALQSPCISYLVAFIEQAEQTALGVANQH 
M,Bright     -------TG------------ASGSTVSGGQVGLPGVSTPTMSSTSNNSLP--------- 
D,dead ringer-----------------------SETRTSSPCHAEAPTVEEEKDEEEEEEEEPKAAEEES 
Y,SWI1       ---GNKDSSFNFNKNLPFVWLSSEENIGSGLLKLSEIILNINNSTSKNTLLQQQNYSKVL 
HELD/Osa1    NLMHMQ-PPPLEPPSVDMMCRAAKALLAMARVDENRSEFLLHEGRLLDISISAVLNSLVA
HOsa2        NLMHMQ-PPPLEPPSVDMMCRAAKALLAMARVDENRSEFLLHEGRLLDISISAVLNSLVA 
R6A3-5       TLMHMQ-PPPLEPPSVDMMCRAAKALLAMARVDQNRSEFLLHEGRLLDISISAVLNSLVA 
HOsa1        SLLHMQ-NPPFEPTSVDMMRRAARALLALAKVDENHSEFTLYESRLLDISVSPLMNSLVS 
MOsa1        SLLHMQ-NPPFEPTSVDMMRRAPRALLALAKVDENHSEFTLYESRLLDISVSPLMNSLVS 
D,EYELID     GINYLRENPDSMGTSLDMLRRAAGTLLHLAKHPDNRSLFMQQEQRLLGLVMSHILDQQVA 
M,Bright     ------------------------------------------------------------ 
D,dead ringerHRSPVK----QENEDADQDMEGSEVLLNGGASAVGG--AGAGVG--VGVGVPLLKDAVVS 
Y,SWI1       LPSINISCVQLIKCLVEKSICFENCLNNDPEILKKIASIPNLFPTDLEIFQLFTNPSVDI 
HELD/Osa1 SVICDVLFQIGQL-----------------------------------------------
HOsa2        SVICDVLFQIGQL----------------------------------------------- 
R6A3-5       SVICDVLFQIGQL----------------------------------------------- 
HOsa1        QVICDVLFLIGQS----------------------------------------------- 
MOsa1        QVICDVLFLIGQS----------------------------------------------- 
D,EYELID     LIISRVLYQVSRGTGPIHSVEFRLLQQRQQQQLRPGPAGKQAASAGGSATVKAETASTET 
M,Bright     ------------------------------------------------------------ 
D,dead ringer------------------------------------------------------------ 
Y,SWI1       QIINQYQLLYNLKNDILTNLE--------------------------------------- 
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(c)
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6A3-5 mAb
(a)
NFKB
(b)
Isotype
control
(c)
α-actin
(d)
Figure 3: 6A3-5/Osa2 cellular localization on VSMC. Actin was used as a cytoplasmic control of smooth muscle cells marker, while NFKB
served as a nuclear control. Cell nucleus was labelled with an anti-6A3-5/Osa2 or an anti-NFKB antibody in comparison to isotype control
(mouse IgG).
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Figure 4: 6A3-5 and α-actin SMC expression in diﬀerent vascular SMC. (a) Levels of 6A3-5 gene transcription were compared, by northern
blot, between the contractile (passage 0, P0) and the secretory/synthetic phenotype (9th passage, P9). Phenotypes were characterized by the
α-actin SMC marker. The 18S served as a control for loading and quantiﬁcation. (b) Quantiﬁcation of 6A3-5 signals, done on 3 indepen-
dent northern blots, reported to the 18S levels. Results show 6A3-5 mRNA levels to be increased by 3 folds in synthetic cells compared to
contractile cells.
SM22-alpha, was observed in LH but not LL rats (Figures
8(b), 8(c)).
Immunolabelling indicated the presence of 6A3-5/Osa2
in VSMC of LH and LL aortas (Figures 9(a), 9(b)), but no
labelling was observed in negative controls (Figure 9(e)). In-
terestingly, the 6A3-5/Osa2 antibody shows similar labelling
to those observed with proto-oncogene c-fos (Figures 9(c),
9(d)). Such an increased level of 6A3-5/Osa2 was associ-
ated with a state of hypertension. Indeed, work by Aguilar
et al [16] has shown that LH rats have a systolic blood pres-
sure (SBP) of 166 ± 3.59 compared to 131 ± 2.78mmHg for
LL.10 Journal of Biomedicine and Biotechnology
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Figure 5: Time course and dose eﬀect of PDGF on 6A3-5/Osa2 expression. (a) Time course of 6A3-5/Osa2 mRNA level analysed by Northern-
blot, following treatment of human proliferating VSMC (9th passage) with 20ng/ml PDGF. VSMC were serum starved for 48 hours before
analysis.(b)Doseeﬀectof6A3-5/Osa2mRNAlevelanalysedbyNorthern-blot,followingtreatmentofVSMCwithincreasingconcentrations
of PDGF for 2 hours. (c) Time course of 6A3-5/Osa2 protein levels investigated by Western blot. (d) Dose eﬀect of 6A3-5/Osa2 protein levels
investigated by Western blot, following VSMC treatment with increasing concentrations of PDGF for 4 hours. The results are representative
of three independent experiments. Northern-blots were quantiﬁed by Quantity One tool (Bio-Rad) and normalized by 18S rRNA level.
Data are presented as means ± SEM.∗ : P<. 05 versus nonstimulated control cells. The Coomassie blue-stained gel indicates equal protein
loading.
Expressionof6A3-5/Osa2andvascularphenotype
inACEinhibitortreatedLHandLLrats
Four-week treatment with Perindopril (an ACE inhibitor)
signiﬁcantly reduced SBP in both LH (from 166 ± 3.59
to 134 ± 1.84mmHg) and LL (from 131 ± 2.78 to 104 ±
2.39mmHg) compared to untreated animals [16]. Inter-
estingly, the 6A3-5/Osa2-gene expression level decreased
in treated LH, but not LL, rats (Figure 10(a)). Moreover,
VSMC contractile markers showed, by Q-PCR, a decreaseGwenaele Garin et al 11
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Figure 6: Inhibition of 6A3-5/Osa2 expression by ODN3 antisense. (a) Western blot of 6A3-5/Osa2 protein expression, following 4 hours
of PDGF-BB stimulation. Serum starved VSMC (0) were treated, ﬁrst, by 6A3-5/Osa2-ODN3 sense (S), antisense (AS), mismatched (Mis),
scrambled(Scr),orvehicle(NT)at200nM.(b)Northernblotof6A3-5/Osa2mRNAexpression,following4hoursofPDGF-BBstimulation.
(c) Quantiﬁcation of Northern blot results, which are representative of three independent experiments. (d) Western blot of 6A3-5/Osa2
protein expression, following 4 hours of PDGF-BB stimulation. Serum starved VSMC (0) were treated, ﬁrst, by 6A3-5/Osa2-ODN3 sense or
antisense at diﬀerent concentrations (25, 100, and 200nM).
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Figure 7: Inhibition of PDGF-stimulated VSMC proliferation by antisense ODN3. (a) Serum starved VSMC were treated by ODN3 sense,
antisense, mismatched, and scrambled oligos at 200nM followed by PDGF-BB (20ng/ml) stimulation for 0 or 24 hours in presence of BrdU.
(b)SerumstarvedVSMCweretreatedbyODN3senseandantisense(at50,100,or200nM)following0and24hoursofPDGF-BB(20ng/ml)
stimulation. Untreated VSMC are used as controls of proliferation rate. The results are representative of four independent experiments. Data
are presented as means ± SEM.∗ : P<. 05 versus nontransfected cells (NT).
in calponin and SM22-alpha in both LH and LL animals
(Figures 10(b), 10(c)). However, Vessel wall media thick-
ness in LH and LL was not aﬀected by such a treatment
(Figure 11(c)).
Expressionof6A3-5/Osa2andvascularphenotype
inAngiotensinII-perfusedLHandLLrats
Perindopril treatment, of the 2 strains, was followed by
chronic perfusion of AngII which showed, over a period12 Journal of Biomedicine and Biotechnology
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Figure 8: Expression of 6A3-5/Osa2 and vascular phenotype in LH versus LL rats. (a) 6A3-5/Osa2 aortic mRNA expression is signiﬁcantly
higher in hypertensive (LH) compared to normotensive (LL) rats. (b) Calponin (VSMC contractile phenotype marker) aortic mRNA gene
expressionissigniﬁcantlyreducedinLHversusLLrats.(c)SM22alpha(VSMCcontractilephenotypemarker)aorticmRNAgeneexpression
is signiﬁcantly reduced in LH versus LL rats. Results are indicated as a ratio of mRNA expression in comparison to 18S expression. Data are
presented as means ± SEM.∗ : P<. 05 versus LL normotensive rats.
of 4 weeks, an increase of SBP in LH (from 134 ± 1.84 to
231 ± 5.67mmHg) and a steady SBP (from 104 ± 2.39 to
192 ± 5.46mmHg) in LL rats [16]. AngII induces a signiﬁ-
cant upregulation of aortic 6A3-5/Osa2 excised from hyper-
tensive (LH) rats in comparison to their unperfused con-
trols(Figure 10(a)). Moreover, decrease in VSMC contractile
markers, closely followed the hypertrophy state of the ves-
sel wall in these two strains (Figures 10(b), 10(c)). In con-
trast, aortic 6A3-5/Osa2-gene expression was not modiﬁed
in normotensive (LL) rats. One should note that AngII per-
fusion induced a signiﬁcant aortic media hypertrophy in LH
(Figure 11(c))a n dt oam u c hl e s s e re x t e n ti nL Lr a t si nc o m -
parison to their unperfused controls (Figure 11(c)).
DISCUSSION
This study reports the cloning and the characterization of
a new gene (6A3-5/Osa2) overexpressed in proliferating rat
vascular smooth muscle cells. Several lines of evidence show
that this new gene is an early-gene activator that may be im-
plicated in the control of VSMC activities.
6A3-5/Osa2 protein bears a DNA binding motif called
ARID and two recently described conserved motifs, OHD1
and OHD2. These functional domains deﬁne the recently
described Osa family of transcription modulator. Recently,
Hurlstone et al [14] cloned the human homologue of 6A3-
5 and showed that the OHD2 motif is necessary for bindingGwenaele Garin et al 13
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Figure 9: Localization of 6A3-5/Osa2 in aortas from LH and LL rats. (a) 6A3-5/Osa2 labelling is observed in SMC of the inner media from
AngII-perfused LH rats (X40). (b) 6A3-5/Osa2 labelling is observed in SMC of the inner media from AngII-perfused LL rats. (c) c-fos
antibody showed a similar localization to 6A3-5/Osa2 in LH rats. (d) c-fos antibody showed a similar localization to 6A3-5/Osa2 in LL
rats. (e) Negative control showed no labelling. Similar localization and labelling was observed for 6A3-5/Osa2 for all tested aortas (data not
shown).
BRG-1 (Brahma-related gene-1), a key catalytic component
of the SWI/SNF-A chromatin remodelling complex. In con-
trast to other ARID proteins, Osa proteins show no se-
quence preference for AT rich sites. Nonetheless, work using
Drosophila suggest that Osa proteins may participate in tar-
geting SWI/SNF to a subset of promoters in vivo and induce
the activation or repression of target gene expression. Prior
to our study, no Osa protein had been described in vascu-
lar cells, and very little is known about the function of these
proteins in mammals.
In this study, we have observed, in a similar way to c-fos,
an early upregulation of 6A3-5/Osa2 soon after mitogenic
stimulation of human or rat VSMC by PDGF-BB. Increased
activity of the PDGF signalling pathway has been implicated
as a contributing factor in the progression of atherosclerosis
or restenosis. PDGF induces activation and phosphorylation
of several cytosolic signalling molecules and nuclear tran-
scription factors, including Egr-1 (early growth response-1),
Ets-1, c-fos,a n dc-jun, which stimulate expression of their
target genes. These data indicate that 6A3-5/Osa2 is an early
PDGF-respondinggenepotentiallyimplicatedinVSMCpro-
liferation. To validate this hypothesis, we generated four spe-
ciﬁc sets of ODN antisense directed against 6A3-5/Osa2.
Only one of these, ODN3, is able to inhibit 6A3-5/Osa2 ex-
pression at the mRNA and the protein level in dose and
sequence-dependant manner. It is interesting to note that
ODN3 targets the ATG initiation site. Previous studies have
demonstrated that such targeting is very eﬀective in inhibit-
ing gene expression by antisense phosphorothioate oligonu-
cleotides.Indeed,ODNcontrolsusedinthepresentstudyin-
dicated that 6A3-5/Osa2 RNA and protein depletion was due
to a sequence-speciﬁc antisense eﬀect, as neither the sense
nor the scrambled or mismatched control ODNs caused
6A3-5/Osa2 depletion. Moreover, we observed no eﬀect on
p53 gene expression following Osa2 inhibition, suggesting
that ODNAS inhibit selectively 6A3-5 expression. We then
usedODN3inassociationwithBrdUincorporationassaysto
assess the role of 6A3-5/Osa2 in VSMC proliferation. ODN3
antisense was able to signiﬁcantly reduce proliferation of
PDGF-stimulated VSMC in a dose and sequence-dependent
manner. Recently, Watanabe et al [22] produced the ﬁrst ev-
idence that an ARID protein family member is implicated
in diﬀerentiation and control of VSMC proliferation. Their
studyshowedthatoverexpressionofMrf2inducesexpression14 Journal of Biomedicine and Biotechnology
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Figure 10:Expressionof6A3-5/Osa2andvascularphenotypeinACEinhibitortreatedLHandLLrats.(a)6A3-5/Osa2aorticmRNAexpression
inuntreatedLHandLLrats(controls)wascomparedtoACEinhibitortreatedratsintheabsence(AceI)orpresenceofperfusedANGII(Ace
I + ANGII). 6A3-5/Osa2 gene expression is downregulated by the ACE inhibitor and upregulated by exogenous AngiotensinII in LH rats.
(b) Calponin gene expressions were quantiﬁed in these same animals. (c) SM22 alpha gene expressions were also quantiﬁed in these same
animals. Results are indicated as a ratio of 6A3-5/Osa2 mRNA expression in comparison to 18S expression. Data are presented as means
±SEM.∗ : P<. 05 versus controls untreated rats, for each strain.
of speciﬁc smooth muscle marker, such as alpha-actin and
SM-22alpha. Interestingly, in contrast to 6A3-5/Osa2, Mrf2
retarded cellular proliferation. It is interesting to note that
Mrf-2 binds a speciﬁc DNA sequence (AATA(C/T)) in con-
trast to Osa proteins. The apparent functional divergence
in regard to cellular proliferation between the two ARID-
bearing proteins could be linked to diﬀerent properties of
their DNA binding activities. The mechanism by which 6A3-
5/Osa2 inﬂuences cell proliferation is unknown. However,
human Osa2 was recently shown, to stimulate transcription
asacofactorofglucocorticoidreceptor-dependenttranscrip-
tional activation in cultured mammalian cells [25]. Inter-
estingly, glucocorticoids are known to modulate prolifera-
tion and expression of some target genes in VSMC (such
as IκB, NaKATPase, adrenomedullin). Further investigation
will be necessary to investigate by which molecular mecha-
nisms, that is, by which target genes 6A3-5/Osa2 inﬂuences
VSMC proliferation.
In a similar way to PDGF, we have previously observed
an early upregulation of 6A3-5/Osa2 in cultured rat VSMC
in response to AngII [15]. Several signalling responses are
shared between PDGF and AngII activation. Indeed, AngII
stimulation of VSMC is associated, in a similar manner to
PDGF, with an upregulation of early activated genes such as
c-fos and c-myc and growth factors such as PDGF and bFGF
[9]. ACE inhibition by perindopril induces a reduction of c-
fos and c-jun expression in response to balloon injury [26].
In vitro study has shown a link between AngII receptor and
PDGFβ receptor in cultured VSMC [27]. Moreover, AngII
has recently been reported to transactivate the PDGFβ re-
ceptor by cross-talk in stroke-prone SHR rats by compari-
son, Wistar-Kyoto rats their normotensive controls, did not
show this eﬀect [28] .I nt h i ss t u d y ,h y p e r t e n s i v er a t s( L H )
had signiﬁcantly higher aortic 6A3-5/Osa2 gene expression
levels in comparison to normotensive rats (LL). Moreover,
while perindopril treatment reduced blood pressure in these
2 strains, it only aﬀected 6A3-5/Osa2-gene expression in LH
but not LL. Finally, exogenous AngII perfusion in the pres-
ence of ACE inhibitor increased blood pressure levels in both
strainsbutincreased6A3-5/Osa2-geneexpressiononlyinLHGwenaele Garin et al 15
LH
(a) (b) (c)
LL
Controls
(d)
Ace I
(e)
Ace I
+ ANGII
(f)
Controls Ace I Ace I
+ ANGII
Controls Ace I Ace I
+ ANGII
Treatment
0
10
20
30
40
50
60
70
M
e
d
i
a
t
h
i
c
k
n
e
s
s
(
u
m
)
c,
￿
￿
#
￿ : P<. 05
# : P<. 05
c : P<. 05
Normotensive (LL) Hypertensive (LH)
(g)
Figure 11: Analysis of media hypertrophy. Media thickness was determined, following haematoxylin/eosin staining of aorta sections. (a)
Control LH rats were studied for their media thickness. (b) AceI treated LH rats were also analysed. (c) AceI and ANGII treated LH rats.
(d) Control LL rats. (e) AceI treated LL rats. (f) AceI + ANGII treated LL rats. (g) Quantiﬁcation of the above data is presented as means
± SEM∗ : P<. 05 versus controls for each strain. # : P<0.05 versus normotensive controls rats, c : P<. 05 versus AngII-perfused
normotensive rats.
but not LL. Interestingly, Kim et al [28] have reported that
treatment of SHR rats with perindopril signiﬁcantly reduced
aortic PDGF-β receptor phosphorylation and ERKinase ac-
tivity which is restored by chronic (but not acute) infusion
of AngII. It is known that PDGFβ receptor is chronically ac-
tivated in SHR compared to Wistar-Kyoto rats.
While LH rats present a higher blood pressure than LL
rats, similar levels of plasma AngII were reported [29]. In-
terestingly, results by Lantelme et al [30], have shown that
inhibition of the renin-angiotensinII system in newborn LH
rats prevents the development of hypertension. It is conceiv-
able that VSMC of LH rats are very much more sensitive to
AngII compared to LL. Such hypersensitivity has been re-
ported for VSMC, isolated from SHR rats, which show ab-
normal growth in vitro with accelerated entry into S phase
of cell cycle and increased cdk2 activity in comparison to
VSMC from Wistar-Kyoto rats [31]. Aortic gene expression
of 6A3-5/Osa2 is signiﬁcantly increased in LH compared to
LL rats. Such enhanced expression of 6A3-5/Osa2 gene in
LH rats may be linked to the potential hypersensitivity of
the VSMC that not only results in increased blood pressure
but modiﬁed phenotype gene markers and media hypertro-
phy. On treatment with an ACE inhibitor, LH rats show a
signiﬁcant reduction in aortic 6A3-5/Osa2 expression, not16 Journal of Biomedicine and Biotechnology
observed in LL rats, that is presumably due to the hypersen-
sitivity of the VSMC to AngII. Chronic perfusion of AngII,
in the presence of an ACE inhibitor, induces a signiﬁcant in-
crease in 6A3-5/Osa2 expression in LH but not in LL rats.
Sabri et al [32], have shown that AngII perfusion induces a
reversion of VSMC to an immature phenotype. Similarily to
AngII, PDGF under in vitro conditions induces suppression
of smooth muscle-speciﬁc gene (-actin and SM22alpha)
through activation of Pi3K/Akt signalling pathways and sub-
cellular redistribution of serum response factor [33]. One
should also note that higher glucocorticoid plasma levels are
observed in LH strains in response to AngII [16]. As previ-
ously indicated, 6A3-5/Osa2 has been implicated as a cofac-
tor of glucocorticoid receptor-dependent transcription [25].
The overall data in this study strongly suggests that the po-
tential hypersensitivity of VSMC, in LH rats, not only con-
trols blood pressure levels but also 6A3-5/Osa2 expression,
gene markers of VSMC phenotype, and media hypertrophy.
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